<DOC>
	<DOC>NCT00998257</DOC>
	<brief_summary>The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.</brief_summary>
	<brief_title>Regulatory Post Marketing Surveillance Study on YAZ</brief_title>
	<detailed_description />
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<criteria>Healthy female subjects requesting contraception suggesting PMDD by Physician who are also requesting contraception with acne who are also requesting contraception Age: 18 50 years Women who is prescribed YAZ first, during study period Women who are contraindicated based on the label of YAZ Presence or a history of venous or arterial thrombotic/ thromboembolic events (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident Presence or history of prodromi of a thrombosis (e.g. transient ischaemic attack, angina pectoris) History of migraine with focal neurological symptoms Diabetes mellitus with vascular involvement The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication Pancreatitis or a history thereof if associated with severe hypertriglyceridemia Presence or history of severe hepatic disease as long as liver function values have not returned to normal Severe renal insufficiency or acute renal failure Presence or history of liver tumours (benign or malignant) Known or suspected sexsteroid influenced malignancies (e.g. of the genital organs or the breasts) Undiagnosed vaginal bleeding Known or suspected pregnancy Hypersensitivity to the active substances or to any of the excipients</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Premenstrual Dysphoric Disorder</keyword>
	<keyword>PMDD</keyword>
	<keyword>Acne</keyword>
</DOC>